NEW DELHI: The government might select enabling Serum Institute of India's (SII) Covovax as a heterologous booster dosage, indicating it can be utilized for people who have actually taken either Covishield or Covaxin for main vaccination versus Covid-19.
Sources stated a conference of the subject specialist committee is set up on Wednesday to ponder on the issue.
The conference is to decide on giving market authorisation to SIIs Covid-19 vaccine Covovax as a heterologous booster dosage for adults who have been administered two doses of Covishield or Covaxin.Prakash Kumar Singh, director of federal government and regulatory affairs at the Serum Institute of India (SII), had actually written a letter to the Drugs Controller General of India (DCGI) just recently for the approval to Covovax as a heterologous booster dosage for adults in view of the escalating pandemic circumstance in some countries, sources said.